Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2019 | May 13, 2019 | |
Document Information [Line Items] | ||
Entity Registrant Name | GeoVax Labs, Inc. | |
Entity Central Index Key | 0000832489 | |
Trading Symbol | govx | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Common Stock, Shares Outstanding (in shares) | 610,089 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Mar. 31, 2019 | Dec. 31, 2018 |
ASSETS | ||
Cash and cash equivalents | $ 175,985 | $ 259,701 |
Grant funds and other receivables | 160,277 | 121,814 |
Prepaid expenses and other current assets | 111,647 | 238,189 |
Total current assets | 447,909 | 619,704 |
Property and equipment, net (Note 5) | 13,725 | 11,350 |
Deposits | 11,010 | 11,010 |
Total assets | 472,644 | 642,064 |
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIENCY) | ||
Accounts payable | 253,166 | 125,859 |
Accrued expenses (Note 6) | 1,378,710 | 1,238,552 |
Current portion of notes payable (Note 7) | 12,500 | 260,420 |
Total current liabilities | 1,644,376 | 1,624,831 |
Note payable, net of current portion (Note 7) | 35,417 | 39,580 |
Total liabilities | 1,679,793 | 1,664,411 |
Commitments (Note 8) | ||
Stockholders’ equity (deficiency): | ||
Common stock, $.001 par value: authorized shares – 600,000,000 issued and outstanding shares – 556,489 and 437,807 at March 31, 2019 and December 31, 2018, respectively | 556 | 438 |
Additional paid-in capital | 37,898,525 | 37,482,766 |
Accumulated deficit | (41,178,338) | (40,476,884) |
Total stockholders’ equity (deficiency) | (1,207,149) | (1,022,347) |
Total liabilities and stockholders’ equity (deficiency) | 472,644 | 642,064 |
Series B Convertible Preferred Stock [Member] | ||
Stockholders’ equity (deficiency): | ||
Convertible Preferred Stock | 76,095 | 76,095 |
Series C Convertible Preferred Stock [Member] | ||
Stockholders’ equity (deficiency): | ||
Convertible Preferred Stock | 705,238 | |
Series E Convertible Preferred Stock [Member] | ||
Stockholders’ equity (deficiency): | ||
Convertible Preferred Stock | 1,190,000 | |
Conversion of Series F Preferred Stock Into Common Stock [Member] | ||
Stockholders’ equity (deficiency): | ||
Convertible Preferred Stock | 1,591,763 | |
Series G Convertible Preferred Stock and Related Warrants [Member] | ||
Stockholders’ equity (deficiency): | ||
Convertible Preferred Stock | $ 404,250 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Mar. 31, 2019 | Dec. 31, 2018 |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 600,000,000 | 600,000,000 |
Common stock, shares issued (in shares) | 556,489 | 437,807 |
Common stock, shares outstanding (in shares) | 556,489 | 437,807 |
Series B Convertible Preferred Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 1,000 | $ 1,000 |
Preferred stock, shares issued (in shares) | 100 | 100 |
Preferred stock, shares outstanding (in shares) | 100 | 100 |
Series C Convertible Preferred Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 1,000 | $ 1,000 |
Preferred stock, shares issued (in shares) | 0 | 2,150 |
Preferred stock, shares outstanding (in shares) | 0 | 2,150 |
Series E Convertible Preferred Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 1,000 | $ 1,000 |
Preferred stock, shares issued (in shares) | 0 | 1,200 |
Preferred stock, shares outstanding (in shares) | 0 | 1,200 |
Conversion of Series F Preferred Stock Into Common Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 1,000 | $ 1,000 |
Preferred stock, shares issued (in shares) | 2,583 | 0 |
Preferred stock, shares outstanding (in shares) | 2,583 | 0 |
Series G Convertible Preferred Stock and Related Warrants [Member] | ||
Preferred stock, par value (in dollars per share) | $ 1,000 | $ 1,000 |
Preferred stock, shares issued (in shares) | 500 | 0 |
Preferred stock, shares outstanding (in shares) | 500 | 0 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Grant and collaboration revenues | $ 364,232 | $ 221,299 |
Operating expenses: | ||
Research and development | 555,718 | 486,994 |
General and administrative | 510,064 | 357,228 |
Total operating expenses | 1,065,782 | 844,222 |
Loss from operations | (701,550) | (622,923) |
Other income (expense): | ||
Interest income | 1,224 | 1,318 |
Interest expense | (1,128) | (208) |
Total other income (expense) | 96 | 1,110 |
Net loss | $ (701,454) | $ (621,813) |
Basic and diluted: | ||
Net loss per common share (in dollars per share) | $ (1.43) | $ (2.50) |
Weighted average shares outstanding (in shares) | 491,707 | 248,340 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Changes In Stockholders' Equity (Deficiency) (Unaudited) - USD ($) | Common Stock [Member] | Series B Convertible Preferred Stock [Member] | Series C Convertible Preferred Stock [Member] | Series D Convertible Preferred Stock [Member] | Series E Convertible Preferred Stock [Member] | Series F Convertible Preferred Stock [Member] | Series G Convertible Preferred Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2017 | 213,474 | 100 | 2,570 | 1,000 | ||||||
Balance at Dec. 31, 2017 | $ 213 | $ 76,095 | $ 842,990 | $ 980,000 | $ 35,696,435 | $ (37,916,790) | $ (321,057) | |||
Sale of convertible preferred stock for cash (in shares) | 600 | |||||||||
Sale of convertible preferred stock for cash | $ 590,000 | 590,000 | ||||||||
Issuance of common stock for services (in shares) | 10,000 | |||||||||
Issuance of common stock for services | $ 10 | 199,990 | 200,000 | |||||||
Conversion of preferred stock to common stock (in shares) | 60,000 | (450) | ||||||||
Conversion of preferred stock to common stock | $ 60 | $ (441,000) | 440,940 | |||||||
Stock-based compensation expense | 23,978 | 23,978 | ||||||||
Net loss | (621,813) | (621,813) | ||||||||
Balance (in shares) at Mar. 31, 2018 | 283,474 | 100 | 2,570 | 550 | 600 | |||||
Balance at Mar. 31, 2018 | $ 283 | $ 76,095 | $ 842,990 | $ 539,000 | $ 590,000 | 36,361,343 | (36,538,603) | (128,892) | ||
Balance (in shares) at Dec. 31, 2018 | 437,807 | 100 | 2,150 | 1,200 | ||||||
Balance at Dec. 31, 2018 | $ 438 | $ 76,095 | $ 705,238 | $ 1,190,000 | 37,482,766 | (40,476,884) | (1,022,347) | |||
Sale of convertible preferred stock for cash (in shares) | 500 | |||||||||
Sale of convertible preferred stock for cash | $ 404,250 | 85,750 | 490,000 | |||||||
Conversion of preferred stock to common stock (in shares) | 118,280 | (587) | (180) | |||||||
Conversion of preferred stock to common stock | $ 118 | $ (192,557) | $ (110,918) | 303,357 | ||||||
Stock-based compensation expense | 26,652 | 26,652 | ||||||||
Net loss | (701,454) | (701,454) | ||||||||
Exchange of preferred stock (in shares) | (1,563) | (1,200) | 2,763 | |||||||
Exchange of preferred stock | $ (512,681) | $ (1,190,000) | $ 1,702,681 | |||||||
Fractional shares issuable upon reverse stock split (in shares) | 402 | |||||||||
Balance (in shares) at Mar. 31, 2019 | 556,489 | 100 | 2,583 | 500 | ||||||
Balance at Mar. 31, 2019 | $ 556 | $ 76,095 | $ 1,591,763 | $ 404,250 | $ 37,898,525 | $ (41,178,338) | $ (1,207,149) |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Cash flows from operating activities: | ||
Net loss | $ (701,454) | $ (621,813) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 1,897 | 4,980 |
Stock-based compensation expense | 153,224 | 52,549 |
Changes in assets and liabilities: | ||
Grant funds and other receivables | (38,463) | 54,758 |
Prepaid expenses and other current assets | (30) | 20,848 |
Accounts payable and accrued expenses | 267,465 | 107,105 |
Total adjustments | 384,093 | 240,240 |
Net cash used in operating activities | (317,361) | (381,573) |
Cash flows from investing activities: | ||
Purchase of property and equipment | (4,272) | |
Net cash used in investing activities | (4,272) | |
Cash flows from financing activities: | ||
Net proceeds from sale of preferred stock | 240,000 | 590,000 |
Proceeds from issuance of note payable | 50,000 | |
Principal repayment of note payable | (2,083) | |
Net cash provided by financing activities | 237,917 | 640,000 |
Net increase (decrease) in cash and cash equivalents | (83,716) | 258,427 |
Cash and cash equivalents at beginning of period | 259,701 | 312,727 |
Cash and cash equivalents at end of period | $ 175,985 | $ 571,154 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Series G Convertible Preferred Stock Issued in Exchange for Cancellation of Term notes Payable [Member] | ||
Convertible note, shares issued (in shares) | 250 | |
Convertible note, value | $ 250,000 | |
Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member] | ||
Convertible preferred stock (in shares) | 1,563 | |
Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member] | ||
Convertible preferred stock (in shares) | 1,200 | |
Conversion of Series C and Series E Preferred Stock Into Series F Preferred Stock [Member] | ||
Conversion of stock, shares issued (in shares) | 2,763 | |
Conversion of Series C Preferred Stock Into Common Stock [Member] | ||
Convertible preferred stock (in shares) | 587 | |
Conversion of stock, shares issued (in shares) | 78,280 | |
Conversion of Series F Preferred Stock Into Common Stock [Member] | ||
Convertible preferred stock (in shares) | 180 | |
Conversion of stock, shares issued (in shares) | 40,000 | |
Conversion From Series D Convertible Preferred Stock To Common Stock [Member] | ||
Convertible preferred stock (in shares) | 450 | |
Conversion of stock, shares issued (in shares) | 60,000 |
Note 1 - Description of Busines
Note 1 - Description of Business | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancers using a novel patented Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. In this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into highly effective VLP immunogens in the person being vaccinated. The MVA-VLP virus replicates to high titers in approved avian cells for manufacturing but cannot productively replicate in mammalian cells. Therefore, the GeoVax MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live attenuated virus, while providing the safety characteristics of a replication-defective vector. Our current development programs are focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. We believe our technology and vaccine development expertise are well-suited for a variety of human infectious diseases and we intend to pursue further expansion of our product pipeline. Our corporate strategy is to improve health to patients worldwide by advancing our vaccine platform, using its unique capabilities to design and develop an array of products addressing unmet medical needs in the areas of infectious diseases and oncology. We aim to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area. |
Note 2 - Basis of Presentation
Note 2 - Basis of Presentation | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Basis of Accounting [Text Block] | 2. The accompanying condensed consolidated financial statements at March 31, 2019 three March 31, 2019 2018 not 10 December 31, 2018. not As described in Note 12, April 30, 2019, one five hundred Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We believe that our existing cash resources, government funding commitments, and equity funding commitments discussed in Note 9 third 2019. not may not |
Note 3 - Summary of Significant
Note 3 - Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 3. We disclosed in Note 2 10 December 31, 2018 no 10 In February 2016, No. 2016 02, Leases 2016 02 2016 02 not 12 12 2016 02 January 1, 2019; no 12 8 There have been no three March 31, 2019, 10 December 31, 2018, |
Note 4 - Basic and Diluted Loss
Note 4 - Basic and Diluted Loss Per Common Share | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 4. Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares and potentially dilutive common share equivalents outstanding during the period. Potentially dilutive common share equivalents consist of convertible preferred stock, stock options and stock purchase warrants. Common share equivalents which potentially could dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, as the effect would be anti-dilutive, totaled approximately 589,000 446,000 March 31, 2019 2018, |
Note 5 - Property and Equipment
Note 5 - Property and Equipment | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | 5. Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of March 31, 2019 December 31, 2018: March 31, 2019 December 31, 2018 Laboratory equipment $ 534,578 $ 530,306 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 678,868 674,596 Accumulated depreciation and amortization (665,143 ) (663,246 ) Property and equipment, net $ 13,725 $ 11,350 |
Note 6 - Accrued Expenses
Note 6 - Accrued Expenses | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 6. Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of March 31, 2019 December 31, 2018: March 31, 2019 December 31, 2018 Accrued management salaries $ 1,026,467 $ 924,509 Accrued directors’ fees 333,870 295,670 Other accrued expenses 18,373 18,373 Total accrued expenses $ 1,378,710 $ 1,238,552 |
Note 7 - Notes Payable
Note 7 - Notes Payable | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 7. On February 28, 2018, five $50,000. 5%, second $8,333 2019, $12,500 2020, 2021 2022, $2,083 2023. five 358 three March 31, 2019 2018 $621 $208, On December 27, 2018, two $250,000. three 20,000 February 2019, 9 |
Note 8 - Commitments
Note 8 - Commitments | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Commitments Disclosure [Text Block] | 8. Lease Agreement We lease approximately 8,400 December 31, 2019, December 31, 2022. three March 31, 2019 2018 $40,316 $39,136, $120,949 2019. one 90 Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of March 31, 2019, $487,000 2019. |
Note 9 - Stockholders' Equity
Note 9 - Stockholders' Equity | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 9. Series B Preferred Stock As of March 31, 2019, 100 may $175 three March 31, 2019, no Series F Preferred Stock On February 18, 2019, 2,763 $1,000 no not $7.50 90% may, During January February 2019 ( 587 78,280 March 2019 ( 180 40,000 March 31, 2019, no 2,583 Series G Preferred Stock On February 25, 2019, 1,000 $1.0 three $1,000 no not $7.50 90% may, At the first February 26, 2019, 500 $250,000 7 $250,000. first 33,334 $7.50 six five first may, Within 50 60 first may $250,000 second 110 to120 first may $250,000 third second third may 66,668 During the three March 31, 2019, no Common Stock Transactions As discussed above, during the three March 31, 2019, 118,280 Stock Options During the three March 31, 2019, no March 31, 2019, 29,441 $53.19/share 13,585 $93.92/share Stock Purchase Warrants During the three March 31, 2019, 33,334 March 31, 2019, 148,032 $11.54/share 94,698 $12.75/share Stock-Based Compensation Expense Stock-based compensation expense related to our stock option plans was $26,652 $23,978 three March 31, 2019 2018, March 31, 2019, $183,731 2.0 Additionally, during the three March 31, 2019 2018 $126,572 $28,571, March 31, 2019, $72,509 second 2019. |
Note 10 - Income Taxes
Note 10 - Income Taxes | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 10. Because of our historically significant net operating losses, we have not 382 |
Note 11 - Grants and Collaborat
Note 11 - Grants and Collaboration Revenue | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Government Grants and Contracts [Text Block] | 11. We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three March 31, 2019 2018, $354,319 $216,299, March 31, 2019, $2,525,419 2019 2020. During the three March 31, 2019 2018, $9,913 $5,000, third |
Note 12 - Subsequent Events
Note 12 - Subsequent Events | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 12. Preferred Stock Transactions On April 26, 2019, $250,000 250 9 33,334 May 2019, 94 53,600 Reverse Stock Split On April 30, 2019, one five hundred |
Note 5 - Property and Equipme_2
Note 5 - Property and Equipment (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | March 31, 2019 December 31, 2018 Laboratory equipment $ 534,578 $ 530,306 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 678,868 674,596 Accumulated depreciation and amortization (665,143 ) (663,246 ) Property and equipment, net $ 13,725 $ 11,350 |
Note 6 - Accrued Expenses (Tabl
Note 6 - Accrued Expenses (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | March 31, 2019 December 31, 2018 Accrued management salaries $ 1,026,467 $ 924,509 Accrued directors’ fees 333,870 295,670 Other accrued expenses 18,373 18,373 Total accrued expenses $ 1,378,710 $ 1,238,552 |
Note 2 - Basis of Presentation
Note 2 - Basis of Presentation (Details Textual) | Apr. 30, 2019 |
Subsequent Event [Member] | Reverse Stock Split [Member] | |
Stockholders' Equity Note, Stock Split, Conversion Ratio | 500 |
Note 4 - Basic and Diluted Lo_2
Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 589,000 | 446,000 |
Note 5 - Property and Equipme_3
Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) | Mar. 31, 2019 | Dec. 31, 2018 |
Property and equipment, gross | $ 678,868 | $ 674,596 |
Accumulated depreciation and amortization | (665,143) | (663,246) |
Property and equipment, net | 13,725 | 11,350 |
Laboratory Equipment [Member] | ||
Property and equipment, gross | 534,578 | 530,306 |
Leasehold Improvements [Member] | ||
Property and equipment, gross | 115,605 | 115,605 |
Other Furniture Fixtures And Equipment [Member] | ||
Property and equipment, gross | $ 28,685 | $ 28,685 |
Note 6 - Accrued Expenses - Sch
Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) | Mar. 31, 2019 | Dec. 31, 2018 |
Accrued management salaries | $ 1,026,467 | $ 924,509 |
Accrued directors’ fees | 333,870 | 295,670 |
Other accrued expenses | 18,373 | 18,373 |
Total accrued expenses | $ 1,378,710 | $ 1,238,552 |
Note 7 - Notes Payable (Details
Note 7 - Notes Payable (Details Textual) - USD ($) | Feb. 28, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | Dec. 27, 2018 |
Proceeds from Notes Payable, Total | $ 50,000 | |||
Interest Expense, Total | 1,128 | 208 | ||
Term Notes [Member] | ||||
Debt Instrument, Face Amount | $ 250,000 | |||
Common Stock Purchase Warrants [Member] | ||||
Warrants and Rights Outstanding, Term | 5 years | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 358 | |||
Warrants issued to two current investors [Member] | ||||
Warrants and Rights Outstanding, Term | 3 years | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 20,000 | |||
Senior Notes [Member] | ||||
Proceeds from Notes Payable, Total | $ 50,000 | |||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | |||
Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year | 8,333 | |||
Long-term Debt, Maturities, Repayments of Principal in Year Two | 12,500 | |||
Long-term Debt, Maturities, Repayments of Principal in Year Three | 12,500 | |||
Long-term Debt, Maturities, Repayments of Principal in Year Four | 12,500 | |||
Long-term Debt, Maturities, Repayments of Principal in Year Five | 2,083 | |||
Interest Expense, Total | $ 621 | $ 208 |
Note 8 - Commitments (Details T
Note 8 - Commitments (Details Textual) | 3 Months Ended | |
Mar. 31, 2019USD ($)ft² | Mar. 31, 2018USD ($) | |
Area of Real Estate Property | ft² | 8,400 | |
Operating Leases, Rent Expense, Total | $ 40,316 | $ 39,136 |
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year | $ 120,949 | |
Lessee, Operating Lease, Renewal Term | 1 year | |
Unrecorded Unconditional Purchase Obligation, Total | $ 487,000 |
Note 9 - Stockholders' Equity (
Note 9 - Stockholders' Equity (Details Textual) - USD ($) | Feb. 28, 2019 | Feb. 26, 2019 | Feb. 18, 2019 | Mar. 31, 2019 | Feb. 28, 2019 | Mar. 31, 2019 | Mar. 31, 2018 | Feb. 25, 2019 | Dec. 31, 2018 | Feb. 28, 2018 |
Preferred Stock, Par or Stated Value Per Share | $ 0.01 | $ 0.01 | $ 0.01 | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | 29,441 | 29,441 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ 53.19 | $ 53.19 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | 13,585 | 13,585 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ 93.92 | $ 93.92 | ||||||||
Share-based Payment Arrangement, Expense | $ 26,652 | $ 23,978 | ||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 183,731 | $ 183,731 | ||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition | 2 years | |||||||||
Stock Issued During Period, Value Expensed During the Period, Issued for Services | $ 126,572 | $ 28,571 | ||||||||
Prepaid Expense, Value of Stock Issued for Services During Period | $ 72,509 | $ 72,509 | ||||||||
Series I Warrants [Member] | ||||||||||
Convertible Preferred Stock and Related Warrants Issued | 33,334 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 7.50 | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 66,668 | |||||||||
Common Stock Purchase Warrants [Member] | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 358 | |||||||||
Class Of Warrant Or Right Issued During Period | 33,334 | |||||||||
Class of Warrant or Right, Outstanding | 148,032 | 148,032 | ||||||||
Class Of Warrant Or Right Outstanding Weighted Average Exercise Price | $ 11.54 | $ 11.54 | ||||||||
Class Of Warrant Or Right Exercisable Number | 94,698 | 94,698 | ||||||||
Class Of Warrant Or Right Exercisable Weighted Average Exercise Price | $ 12.75 | $ 12.75 | ||||||||
Series G Convertible Preferred Stock and Related Warrants [Member] | ||||||||||
Convertible Preferred Stock and Related Warrants, Authorized | 1,000 | |||||||||
Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum | $ 1,000,000 | $ 250,000 | ||||||||
Convertible Preferred Stock and Related Warrants Issued | 500 | |||||||||
Conversion of Series C Preferred Stock Into Common Stock [Member] | ||||||||||
Conversion of Stock, Shares Converted | 587 | 587 | ||||||||
Conversion of Stock, Shares Issued | 78,280 | 78,280 | ||||||||
Conversion of Series F Preferred Stock Into Common Stock [Member] | ||||||||||
Conversion of Stock, Shares Converted | 180 | 180 | ||||||||
Conversion of Stock, Shares Issued | 40,000 | 40,000 | ||||||||
Conversion from Series C and F Convertible Preferred Stock to Common Stock [Member] | ||||||||||
Conversion of Stock, Shares Issued | 118,280 | |||||||||
Series B Convertible Preferred Stock [Member] | ||||||||||
Preferred Stock, Shares Outstanding, Ending Balance | 100 | 100 | 100 | |||||||
Convertible Preferred Stock, Conversion Price1 | $ 175 | $ 175 | ||||||||
Conversion of Stock, Shares Converted | 0 | |||||||||
Preferred Stock, Par or Stated Value Per Share | $ 1,000 | $ 1,000 | $ 1,000 | |||||||
Series F Convertible Preferred Stock [Member] | ||||||||||
Preferred Stock, Shares Outstanding, Ending Balance | 2,583 | 2,583 | ||||||||
Convertible Preferred Stock, Conversion Price1 | $ 7.50 | |||||||||
Number of Series C and Series E Preferred Stock Exchanged for Series F Convertible Preferred Stock | 2,763 | |||||||||
Preferred Stock, Par or Stated Value Per Share | $ 1,000 | |||||||||
Convertible Preferred Stock, Conversion Price, Percentage of Volume Weighted Average Price of the Common Stock | 90.00% | |||||||||
Series E Convertible Preferred Stock [Member] | ||||||||||
Preferred Stock, Shares Outstanding, Ending Balance | 0 | 0 | 1,200 | |||||||
Preferred Stock, Par or Stated Value Per Share | $ 1,000 | $ 1,000 | $ 1,000 | |||||||
Series G Convertible Preferred Stock [Member] | ||||||||||
Convertible Preferred Stock, Conversion Price1 | $ 7.50 | |||||||||
Conversion of Stock, Shares Converted | 0 | |||||||||
Preferred Stock, Par or Stated Value Per Share | $ 1,000 | |||||||||
Convertible Preferred Stock, Conversion Price, Percentage of Volume Weighted Average Price of the Common Stock | 90.00% | |||||||||
Series C Convertible Preferred Stock [Member] | ||||||||||
Preferred Stock, Shares Outstanding, Ending Balance | 0 | 0 | 2,150 | |||||||
Preferred Stock, Par or Stated Value Per Share | $ 1,000 | $ 1,000 | $ 1,000 |
Note 11 - Grants and Collabor_2
Note 11 - Grants and Collaboration Revenue (Details Textual) - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Revenue from Contract with Customer, Including Assessed Tax | $ 364,232 | $ 221,299 |
NIH Grants [Member] | ||
Revenue from Contract with Customer, Including Assessed Tax | 354,319 | 216,299 |
Unused Grant Funds | 2,525,419 | |
Research Agreements [Member] | ||
Revenue from Contract with Customer, Including Assessed Tax | $ 9,913 | $ 5,000 |
Note 12 - Subsequent Events (De
Note 12 - Subsequent Events (Details Textual) | May 12, 2019shares | Apr. 30, 2019 | Apr. 26, 2019USD ($)shares | Mar. 31, 2019shares | Mar. 31, 2019USD ($)shares | Mar. 31, 2018USD ($) |
Proceeds from Issuance of Convertible Preferred Stock | $ | $ 240,000 | $ 590,000 | ||||
Conversion of Series F Preferred Stock Into Common Stock [Member] | ||||||
Conversion of Stock, Shares Converted | 180 | 180 | ||||
Conversion of Stock, Shares Issued | 40,000 | 40,000 | ||||
Series G Convertible Preferred Stock [Member] | ||||||
Conversion of Stock, Shares Converted | 0 | |||||
Subsequent Event [Member] | Reverse Stock Split [Member] | ||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 500 | |||||
Subsequent Event [Member] | Conversion of Series F Preferred Stock Into Common Stock [Member] | ||||||
Conversion of Stock, Shares Converted | 94 | |||||
Conversion of Stock, Shares Issued | 53,600 | |||||
Subsequent Event [Member] | Series I Warrants [Member] | ||||||
Class Of Warrant Or Right Issued During Period | 33,334 | |||||
Subsequent Event [Member] | Series G Convertible Preferred Stock [Member] | ||||||
Proceeds from Issuance of Convertible Preferred Stock | $ | $ 250,000 | |||||
Stock Issued During Period, Shares, New Issues | 250 |